Today: 19 April 2026
Browse Category

NYSE:EW 27 January 2026

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop